While the majority of MPN patients have mutations in the Janus Kinase 2 tyrosine kinase gene (JAK2), a substantial proportion of ET and MF patients with non‐mutated JAK2 have mutations in exon 9 of the CRT gene (CALR). Here, CALR is linked to myeloproliferative neoplasm.